We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

106 hedge funds and large institutions have $1.29B invested in Zentalis Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,496% more call options, than puts

Call options by funds: $1.58M | Put options by funds: $24K

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

60% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 30

9.54% more ownership

Funds ownership: 103.2% → 112.74% (+9.5%)

2% more capital invested

Capital invested by funds: $1.27B → $1.29B (+$27.5M)

12% less funds holding

Funds holding: 120 → 106 (-14)

70% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 20

Holders
106
Holders Change
-14
Holders Change %
-11.67%
% of All Funds
1.7%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.08%
New
6
Increased
48
Reduced
30
Closed
20
Calls
$1.58M
Puts
$24K
Net Calls
+$1.56M
Net Calls Change
-$2.23M

Top Buyers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
+$65.6M
2
APM
Avidity Partners Management
Texas
+$19.9M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$10.7M
4
SI
Sofinnova Investments
California
+$9.05M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.3M

Top Sellers

Rank Fund Capital Flow
1
Axa
Axa
France
-$4.96M
2
WP
Woodline Partners
California
-$3.73M
3
AAA
Affinity Asset Advisors
New York
-$3.68M
4
NIP
Nicholas Investment Partners
California
-$3.44M
5
Walleye Capital
Walleye Capital
New York
-$1.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
MC
26
Mayo Clinic
Minnesota
$5.98M +$6.39M +297,143 New
Bank of America
27
Bank of America
North Carolina
$4.84M +$2.54M +118,205 +97%
UBS AM
28
UBS AM
Illinois
$4.83M +$304K +14,112 +6%
KCM
29
Kennedy Capital Management
Missouri
$4.72M -$181K -8,396 -3%
Norges Bank
30
Norges Bank
Norway
$4.67M – – –
Rafferty Asset Management
31
Rafferty Asset Management
New York
$4.62M +$980K +45,563 +25%
Ameriprise
32
Ameriprise
Minnesota
$4.41M +$742K +34,515 +19%
SAM
33
Sectoral Asset Management
Quebec, Canada
$4.05M +$3.03M +141,000 +235%
Ensign Peak Advisors
34
Ensign Peak Advisors
Utah
$3.93M +$927K +43,080 +28%
OM
35
Opaleye Management
Massachusetts
$3.37M +$3.6M +167,500 New
Bank of New York Mellon
36
Bank of New York Mellon
New York
$3.19M +$116K +5,377 +4%
UBS Group
37
UBS Group
Switzerland
$3.12M +$2.79M +129,897 +520%
WP
38
Woodline Partners
California
$2.95M -$3.73M -173,228 -54%
Voloridge Investment Management
39
Voloridge Investment Management
Florida
$2.94M -$1.36M -63,405 -30%
Morgan Stanley
40
Morgan Stanley
New York
$2.69M +$776K +36,065 +37%
CS
41
Candriam SCA
Luxembourg
$2.58M – – –
Barclays
42
Barclays
United Kingdom
$2.58M +$243K +11,276 +10%
N
43
Nuveen
North Carolina
$2.34M -$161K -7,496 -6%
Swiss National Bank
44
Swiss National Bank
Switzerland
$2.22M +$43K +2,000 +2%
Citigroup
45
Citigroup
New York
$2.05M -$1.44M -66,881 -40%
ECM
46
ExodusPoint Capital Management
New York
$1.73M -$1.56M -72,324 -46%
TD Asset Management
47
TD Asset Management
Ontario, Canada
$1.67M – – –
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$1.57M +$688K +31,999 +70%
Russell Investments Group
49
Russell Investments Group
United Kingdom
$1.48M -$138K -6,415 -8%
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.19M +$75.8K +3,526 +6%
1
2
3 4 5

ZNTL Hedge Fund Activity: Q4 2022 in Review

106 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2022, worth a combined $1.29B — up 2.2% from $1.27B a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ZNTL and 6 opened new positions — a net loss of 14 holders — while 30 trimmed existing stakes and 48 added.

The largest buyer was Capital International Investors, opening a new position worth an estimated $65.6M. The largest seller was Axa, exiting entirely with an estimated $4.96M sold.

  • 106 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2022, down from 120 in Q3 2022.
  • Funds reported $1.29B of Zentalis Pharmaceuticals stock for Q4 2022, up 2.2% quarter-over-quarter.
  • 6 funds opened new Zentalis Pharmaceuticals positions in Q4 2022 and 20 closed out, a net change of -14 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q4 2022 was Capital International Investors, an estimated $65.6M added.
  • The largest Zentalis Pharmaceuticals seller in Q4 2022 was Axa, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2022.